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1 These two authors have equally contributed to thiVery long-chain fatty acids (VLCFAs) have a variety of physiological functions and are related to
numerous disorders. The key step of VLCFA elongation is catalyzed by members of the elongase fam-
ily, ELOVLs. Mammals have seven ELOVLs (ELOVL1-7), yet none of them has been puriﬁed and ana-
lyzed. In the presented study we puriﬁed ELOVL7 and measured its activity by reconstituting it into
proteoliposomes. Puriﬁed ELOVL7 exhibited high activity toward acyl-CoAs with C18 carbon chain
length. The calculated Km values toward C18:3(n-3)-CoA and malonyl-CoA were both in the lM
range. We also found that progression of the VLCFA cycle enhances ELOVL7 activity.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Most cellular lipid molecules include as a major constituent at
least one fatty acid (FA). FAs are diverse in carbon chain length
and degree of saturation, which contributes greatly to the variety
of functions exhibited by the lipids. The most abundant cellular
FAs are long-chain fatty acids (LCFAs) with 16–18 carbons. Very
long-chain fatty acids (VLCFAs), those having a chain length >20
carbons, are less abundant than LCFAs but possess unique func-
tions that cannot be substituted for by LCFAs. LCFAs such as pal-
mitic acid (C16:0), oleic acid (C18:1), and linoleic acid (C18:2)
are mainly utilized as components of glycerophospholipids and tri-
acylglycerol [1], the latter of which is relevant to obesity and
hyperlipidemia. In contrast, most saturated or monounsaturated
VLCFAs are incorporated into sphingolipids and play important
functions in physiological processes such as skin barrier and mye-
lin formation [2,3]. Moreover, polyunsaturated VLCFAs such as
docosahexaenoic acid (C22:6) exhibit anti-inﬂammatory and
anti-atherogenic effects [4].
VLCFAs are synthesized in the endoplasmic reticulum from
LCFAs, which are food-derived or synthesized in the cytosol dechemical Societies. Published by E
, fatty acid; LCFA, long-chain
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s work.novo by FA synthase. VLCFA elongation occurs by cycling through
a 4-step reaction (condensation, reduction, dehydration, and
reduction), with 2 carbons being added through each cycle [5]. In
the ﬁrst reaction acyl-CoA and malonyl-CoA are condensed to 3-
ketoacyl-CoA by one of the FA elongases named the ELOVLs [5].
The second step is an NADPH-dependent reduction catalyzed by
the 3-ketoacyl-CoA reductase KAR to produce 3-hydroxyacyl-CoA
[6], and the third, a dehydration step by one of the 3-hydroxya-
cyl-CoA dehydratases HACD1-4 [7]. The resulting 2,3-trans-enoyl-
CoA is ﬁnally reduced to acyl-CoA by the trans-enoyl-CoA
reductase TER, which is NADPH-dependent [6].
The ELOVLs catalyze the ﬁrst, rate-limiting step of the VLCFA
elongation cycle. In mammals, seven ELOVL isozymes (ELOVL1-7)
exist, and each has a speciﬁc substrate speciﬁcity and physiological
functions [5]. ELOVLs are also associated with known pathologies.
Dominant ELOVL4 mutations cause a juvenile macular dystrophy
(Stargardt disease-3) [8], and Elovl4 knockout mice die soon after
birth due to a deﬁciency in skin barrier formation [9]. Studies in
Elovl6-null mice have revealed that ELOVL6 is involved in an
obesity-induced insulin resistance [10], and ELOVL7 is reportedly
involved in prostate cancer growth [11].
We recently investigated the enzyme activities of all ELOVLs
under identical conditions, and determined the substrate speciﬁc-
ity of each [12]. We demonstrated that ELOVL1 exhibits high activ-
ity toward C20–C22 saturated and monounsaturated acyl-CoAs,
and ELOVL7 elongates C16–C20 acyl-CoAs, with its highest activity
toward C18-CoAs. In that study we determined the activities only
at a ﬁxed concentration (50 lM) of each substrate acyl-CoA, andlsevier B.V. All rights reserved.
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ducing each ELOVL. It is also important, though, to determine both
the Km and Vmax values of puriﬁed enzymes, so as to evaluate the
contribution of each ELOVL to the VLCFA elongation reaction.
Although there have been reports on the enzymatic characteriza-
tion of yeast ELOVL homologs using puriﬁed enzymes [13], there
have been no such reports regarding the mammalian ELOVLs. In
the presented study, we subjected ELOVL7, the least studied of
the mammalian ELOVLs, to puriﬁcation and determination of its
Km and Vmax values. Although ELOVL7 lost its activity when solubi-
lized in Triton X-100, we successfully measured its activity by
reconstituting it into proteoliposomes. Moreover, by comparing
the activity of puriﬁed ELOVL7 with activity in a membrane frac-
tion, we determined that progression of the VLCFA cycle is required
for maximal activity of ELOVL7.
2. Materials and methods
2.1. Cell culture and transfection
HEK 293T cells were grown in 0.3% collagen-coated dishes, in
Dulbecco’s modiﬁed Eagle’s medium (Sigma, St. Louis, MO) con-
taining 10% fetal bovine serum and supplemented with
100 units/ml penicillin and 100 lg/ml streptomycin. Transfections
were performed using Lipofectamine Plus™ Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
The Saccharomyces cerevisiae strain DEY113 (Dprb1::KanMX4
Dpep4::MET15) is a derivative of BY4741 (MATa his3D1 leu2D0
met15D0 ura3D0) [14]. DEY113 cells carrying the pYS15 or
pYS19 plasmid were grown in synthetic complete (SC) medium
(0.67% yeast nitrogen base and 2% D-glucose) containing nutritional
supplements.
2.2. Plasmids
The pCE-puro 3xFLAG-1 plasmid is a mammalian expression
vector designed to produce an N-terminal 3xFLAG-tagged protein.
The pCE-puro 3xFLAG-ELOVL7 plasmid is a derivative of the pCE-
puro 3xFLAG-1 plasmid and encodes 3xFLAG-ELOVL7, as described
previously [12]. The pAK1018 plasmid (URA3 marker) is a yeast
expression vector designed to produce an N-terminal, tandemly
oriented His6, Myc, and 3xFLAG (HMF)-tagged protein under the
control of the TDH3 (glyceraldehyde 3-phosphate dehydrogenase)
promoter. The pYS15 plasmid encoding HMF-ELOVL7 was con-
structed by cloning ELOVL7 cDNA from the pCE-puro 3xFLAG-
ELOVL7 plasmid into the pAK1018 vector. The pYS19 plasmid
encoding HMF-ELOVL7 (AA) was created by site-directed mutagen-
esis using a QuikChange kit (Stratagene, Agilent Technologies, La
Jolla, CA) and primers 50-TTCCTTCATGTATTCGCTGCTACCAT-
CATGCCGTG-30 and 50-CACGGCATGATGGTAGCAGCGAATACATGAA
GGAA-30.
2.3. Puriﬁcation of HMF-ELOVL7
Yeast cells expressing HMF-ELOVL7 or HMF-ELOVL7 (AA) were
suspended in buffer A (50 mM HEPES-NaOH (pH 6.8), 500 mM
NaCl, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsul-
fonyl ﬂuoride, and a 1 protease inhibitor mixture (Complete™
EDTA free; Roche Diagnostics, Indianapolis, IN)) and lysed by
vigorously mixing with glass beads using a BeadBeater (Biospec
Products, Bartlesville, OK). After removal of cell debris by centrifu-
gation (2000g, 3 min, 4 C), the supernatant was centrifuged at
high speed (100000g, 60 min, 4 C). The resulting pellet (mem-
brane fraction) was suspended in buffer A containing 2% Triton
X-100. After an additional high speed centrifugation (100000g,60 min, 4 C), the supernatant (solubilized fraction) was incubated
overnight at 4 C with anti-FLAG M2 agarose (Sigma) while rotat-
ing. The beads were washed six times in decreasing concentrations
of Triton X-100 in buffer A. The bound proteins were then eluted
with buffer A containing 0.1% Triton X-100 and 100 lg/ml 3xFLAG
peptide.
2.4. In vitro FA elongase assay
Membrane fractions used for in vitro elongase assays were
prepared as described previously [12]. Reconstitution of proteins
into proteoliposomes was performed essentially as described
elsewhere [13], using phosphatidylcholine (Avanti Polar Lipids,
Alabaster, AL) as the liposomal lipid and Bio-beads SM-2 adsorbents
(Bio-Rad, Hercules, CA) for adsorption of Triton X-100. In vitro FA
elongation assays were performed as described previously [12].
2.5. Immunoblotting
Immunoblotting was performed as described previously [15],
using the anti-FLAG antibody M2 (1 lg/ml; Stratagene, Agilent
Technologies, La Jolla, CA) as the primary antibody, and HRP-conju-
gated anti-mouse IgG F(ab0)2 fragment (1:7500 dilution; GE
Healthcare Bio-Sciences) as the secondary antibody. Labeling was
detected using Pierce Western Blotting Substrate (Thermo Fisher
Scientiﬁc, Waltham, MA).
3. Results
3.1. Progression of the VLCFA elongation cycle enhances ELOVL7
activity
In our previous report, we determined the substrate speciﬁcity
of ELOVL7 using total membrane proteins prepared from HEK 293T
cells overproducing 3xFLAG-ELOVL7 [12]. In that experiment we
included the reducing agent NADPH, which is required for the sec-
ond and fourth reactions of the VLCFA elongation cycle, but not for
the ELOVL7-catalyzed ﬁrst reaction. Under such conditions, the
ELOVL7 product 3-ketoacyl-CoA was rapidly converted to acyl-
CoA via 3-hydroxyacyl-CoA and 2,3-trans-enoyl-CoA [12]. Here,
we compared the ELOVL7 activity in the presence or absence of
NADPH. Total membrane proteins prepared from HEK 293T cells
transfected with the vector or with a plasmid encoding 3xFLAG-
ELOVL7, were incubated with [14C]malonyl-CoA and C18:3(n-3)-
CoA. After the reaction, the acyl-CoAs produced were converted
to FAs by saponiﬁcation, then separated by TLC. In the presence
of NADPH, the levels of the acyl-CoA generated by the ELOVL7
membrane preparations were much higher than those produced
by control membranes (Fig. 1A, FA), as reported previously [12].
Low levels of 3-hydroxyacyl-CoA were also detected in the reaction
products generated by the ELOVL7membrane preparations. In con-
trast, when the reactions were performed in the absence of NADPH,
3-ketoacyl-CoA, but no acyl-CoA or 3-hydroxyacyl-CoA, was pro-
duced by the ELOVL7 membrane preparations (Fig. 1A). An addi-
tional band (Fig. 1A, asterisk) was also generated by the ELOVL7
membrane preparations, but this may represent a by-product of
3-ketoacyl-CoA, perhaps a decarboxylated form, formed during
the saponiﬁcation reaction. Little 3-ketoacyl-CoA was generated
by control membranes in the absence of NADPH (Fig. 1A). Although
NADPH itself is not involved in the ELOVL7-catalyzed reaction, the
reaction products were more abundant in the presence of NADPH
(Fig. 1A, acyl-CoA plus 3-hydroxyacyl-CoA) than in its absence
(Fig. 1A, 3-ketoacyl-CoA plus 3-ketoacyl-CoA⁄). These results sug-
gest that for ELOVL7 to exert its maximal activity, participation
of the entire VLCFA elongation cycle is required.
Fig. 1. NADPH- and membrane-dependent ELOVL7 activity. Total membrane
proteins were prepared from HEK 293T cells transfected with a vector (pCE-puro
3xFLAG-1) or a plasmid encoding the 3xFLAG-ELOVL7 protein (pCE-puro 3xFLAG-
ELOVL7). (A) Total membrane proteins (10 lg protein) were incubated with 50 lM
C18:3(n-6)-CoA and 0.075 lCi [14C]malonyl-CoA for 30 min at 37 C in the
presence or absence of 1 mM NADPH. After termination of the reactions, lipids
were saponiﬁed, acidiﬁed, extracted, and separated by normal-phase TLC, followed
by detection with a bioimaging analyzer BAS-2500 (Fuji Photo Film, Tokyo, Japan).
keto, 3-keto-FA; ⁄keto, a by-product of 3-keto-FA; hydroxy, 3-hydroxy-FA. (B and
C) Total membrane proteins were prepared from HEK 293T cells transfected with
the pCE-puro 3xFLAG-ELOVL7 plasmid were solubilized with 1% Triton X-100 then
reconstituted into proteoliposomes. (B) In vitro FA elongation assays were
performed with 10 lg protein preparations of total membrane proteins (TM) or
solubilized membrane proteins (SM), or with proteoliposomes prepared from
10 lg (liposome x1) or 40 lg total membrane proteins (liposome x4). (C)
Preparations in (B) (1/20 amounts) were subjected to immunoblotting with an
anti-FLAG antibody.
Fig. 2. Enzyme assays of puriﬁed ELOVL7 reconstituted in proteoliposomes. (A)
DEY113 cells harboring the pYS15 plasmid encoding HMF-ELOVL7 or the pYS19
plasmid encoding HMF-ELOVL7 (AA) were cultured in SC medium lacking uracil.
Cells were harvested and lysed by glass beads, and total membrane proteins were
prepared. Proteins were solubilized with Triton X-100 then subjected to puriﬁca-
tion using anti-FLAG M2 agarose afﬁnity beads. Fixed amounts of puriﬁed proteins
(0.75 lg) were separated by SDS–PAGE and stained with Coomassie brilliant blue.
(B) Puriﬁed proteins (30 ng) were subjected to immunoblotting with an anti-FLAG
antibody. (C) Puriﬁed proteins (1 lg) in solution or reconstituted into proteolipo-
somes were incubated with 50 lM C18:0-CoA and 0.075 lCi [14C]malonyl-CoA for
30 min at 37 C, in the presence or absence of 1 mM NADPH. After termination of
the reactions, lipids were saponiﬁed, acidiﬁed, extracted, and separated by normal-
phase TLC, followed by detection with a bioimaging analyzer BAS-2500. WT, wild
type ELOVL7; MT, mutant ELOVL7; keto, 3-keto-FA; ⁄keto, by-product of 3-keto-FA.
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teins [13], solubilization by a non-ionic detergent such as Triton
X-100 is necessary for puriﬁcation. However, when the ELOVL7
membrane preparations were solubilized with Triton X-100,
ELOVL7 exhibited no enzymatic activity (Fig. 1B). We speculated
that it was necessary for ELOVL7 to be embedded in a lipid bilayer
to exert its activity. We therefore reconstituted solubilized pro-
teins from the ELOVL7 membranes into proteoliposomes by
removing Triton X-100 in the presence of phosphatidylcholine.
Immunoblotting revealed that the reconstitution efﬁciency was
approximately 25%, since a 4-fold (x4) amount of proteoliposomes
contained a similar amount of ELOVL7 protein as compared to the
total membrane and solubilized membrane fraction (Fig. 1C). Pro-
teoliposomes (x4) having an equivalent amount of ELOVL7 exhib-
ited activity similar to that of total membrane preparations
(Fig. 1B). Thus, reconstituting ELOVL7 in proteoliposomes solved
the problem of no activity in solubilized ELOVL7.3.2. Enzyme activity of puriﬁed ELOVL7
To evaluate the activity of puriﬁed ELOVL7 utilizing the
proteoliposome-reconstitution system, we ﬁrst overproduced
His6–Myc–3xFLAG (HMF)-tagged wild type ELOVL7 in yeast. We
also constructed a mutant of the conserved HXXHHmotif and used
it as a negative control. The HXXHH motif is conserved among
ELOVL family members, and its mutation in the yeast ELOVL family
protein Fen1 reportedly results in a loss of activity [13]. In wild
type ELOVL7, the sequence of this motif is HVFHH, so we created
an HVFAA mutant. Both wild type HMF-ELOVL7 proteins and
HMF-ELOVL7 (AA) mutant proteins were overproduced in yeast,
then solubilized with Triton X-100 and puriﬁed. SDS–PAGE and
subsequent Coomassie brilliant blue staining revealed that both
proteins migrated at around 32 kDa (Fig. 2A). Additional bands,
including bands near 70 and 30 kDa were also observed. The
70 kDa band may represent the SDS-resistant dimer, and the
30 kDa band may be a degradation product of HMF-ELOVL7. These
bands were all detected by immunoblotting with anti-FLAG anti-
bodies (Fig. 2B).
We next performed in vitro elongase assays using the puriﬁed
enzymes and the substrate C18:0-CoA. As expected, wild type
HMF-ELOVL7 had no activity when solubilized in Triton X-100,
but it did exhibit activity when reconstituted into proteoliposomes
(Fig. 2C). Inclusion of NADPH did not affect the enzyme activity
(Fig. 2C), conﬁrming that ELOVL7 itself does not require NADPH
for its catalytic reaction. We observed low levels of 3-hydroxya-
cyl-CoA in the presence of NADPH, suggesting slight contamination
of the enzyme preparation by endogenously expressed yeast
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each step of the FA elongation cycle interact with each other and
form an elongase complex both in yeast and mammals
[12,13,16,17], so it is probable that ELOVL7 is able to form an
elongase complex with yeast components including Ybr159w.
However, inclusion of the 3-ketoacyl-CoA reductase or others, if
any, apparently do not affect the results and conclusion, since
the similarly puriﬁed mutant HMF-ELOVL7 (AA) had no enzyme
activity when reconstituted in proteoliposomes (Fig. 2C).
3.3. Substrate speciﬁcity of puriﬁed ELOVL7
Wenext investigated the substrate speciﬁcity of ELOVL7using11
different acyl-CoAs and puriﬁed wild type HMF-ELOVL7 proteins
reconstituted in proteoliposomes. ELOVL7 exhibited activity toward
acyl-CoAswith C16–C20 chain length, irrespective of the number of
double bonds (Fig. 3A and B). The highest activity of ELOVL7
observed was toward C18:3(n-3)-CoA and C18:3(n-6)-CoA. ELOVL7
was also active toward C20:4-, C18:0-, C18:1-, C18:2-, and
C16:0-CoAs, and weakly toward C20:0-CoA. In contrast, little or no
activity was observed toward C22:0-, C24:0-, or C26:0-CoA. TheFig. 3. Substrate speciﬁcity of puriﬁed ELOVL7 enzyme. (A and B) Puriﬁed wild type
HMF-ELOVL7 protein (1 lg) was reconstituted into proteoliposomes and incubated
with the indicated acyl-CoA (50 lM) and 0.075 lCi [14C]malonyl-CoA for 30 min at
37 C. After termination of the reactions, lipids were saponiﬁed, acidiﬁed, extracted,
and separated by normal-phase TLC, followed by detection on X-ray ﬁlm (A) and
quantiﬁcation by a bioimaging analyzer BAS-2500 (B). Values presented are FA
levels generated for each lg protein after 30 min, and represent the mean ± S.D.
from three independent experiments.ELOVL7 substrate speciﬁcity identiﬁed here using puriﬁed enzyme
correlated well with that in our recent report, determined using
crude membrane fractions from cells overproducing ELOVL7 [12].
3.4. Determination of enzyme kinetic parameters of ELOVL7
Determining the kinetic parameters (Km and Vmax) of ELOVL7
and comparing them with parameters of other ELOVLs will be
important to elucidate the actual involvement of ELOVL7 in each
elongation reaction. We examined ELOVL7 activity toward
C18:3(n-3)-CoA, the FA to which ELOVL7 exhibited the highest
activity, at various concentrations. A Lineweaver–Burk plot of the
obtained data revealed a Km value of 2.6 lM and a Vmax value of
0.33 pmol/min/lg protein (Fig. 4A). We also determined the ki-
netic parameters of ELOVL7 toward another substrate, malonyl-
CoA (Km, 11.7 lM; Vmax, 0.31 pmol/min/lg) (Fig. 4B). Thus, the
Km values determined are in the lM range for both acyl-CoA and
malonyl-CoA substrates. Moreover, both plots presented as
straight lines, indicating that ELOVL7 is not regulated by any
homotropic, allosteric effect.
4. Discussion
To date, all in vitro assays for the mammalian VLCFA elongases
known as ELOVLs were performed using total membrane or
microsomal fractions from cells overproducing the studied ELOVL.Fig. 4. Kinetic parameters of ELOVL7. Puriﬁed wild type HMF-ELOVL7 protein
(0.5 lg) was reconstituted into proteoliposomes and incubated with the indicated
concentrations of C18:3(n-3)-CoA and 0.075 lCi (27.3 lM) [14C]malonyl-CoA for
30 min at 37 C (A). The reconstituted HMF-ELOVL7 protein (0.5 lg) was incubated
with 50 lM C18:3(n-3)-CoA and indicated concentrations of [14C]malonyl-CoA for
30 min at 37 C (B). After termination of the reactions, lipids were saponiﬁed,
acidiﬁed, extracted, and separated by normal-phase TLC. The radioactivities
associated with the reaction product FAs were quantiﬁed using a bioimaging
analyzer BAS-2500 and are expressed in a Lineweaver–Burk plot.
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affect the results or the activity of the ELOVL protein under inves-
tigation. For example, unidentiﬁed regulatory proteins can exist in
such fractions, generating differences in the activity of the ELOVL
in crude membranes and that of puriﬁed protein. Therefore, an
in vitro FA elongation assay using puriﬁed enzymes is particularly
important.
Although membrane proteins must be solubilized by detergent
for puriﬁcation, they sometimes exhibit a loss of activity in such a
solubilized state. One possible reason may be structural changes
(denaturation). Alternatively, accessibility between an enzyme
and a substrate, each existing in different micelles, may be com-
promised, especially in the case of hydrophobic substrates. ELOVL7
also lost its activity under solubilized conditions (Figs. 1B and 2C).
This loss is not restricted to ELOVL7, and may be applicable to ELO-
VLs in general, since ELOVL1 and ELOVL6 also have no activity in
the solubilized state (our unpublished data). We successfully ad-
dressed this problem by reconstituting ELOVL7 into proteolipo-
somes, in which ELOVL7 is embedded in a lipid bilayer (Figs. 1B
and 2C). The reconstituted ELOVL7 exhibited activity toward sev-
eral acyl-CoAs of C16–C20 chain length, with the highest activity
toward C18:3(n-3)-CoA and C18:3(n-6)-CoA (Fig. 3A and B). This
substrate speciﬁcity, determined using puriﬁed enzyme, is nearly
identical to our previous results using total membrane fractions
[12], conﬁrming the validity of the analyses. The determined Km
values for ELOVL7 toward C18:3(n-3)-CoA and malonyl-CoA were
both low, in the lM range. These values may be within the range
of actual cellular concentrations, although precise cellular levels
are not known.
The activity of ELOVL7 in total membrane fractions was 12-
fold lower in the absence of NADPH than in its presence
(Fig. 1A), although puriﬁed, reconstituted ELOVL7 exhibited similar
activity regardless of the presence of NADPH (Fig. 2C). ELOVL7 it-
self does not need NADPH for its activity, but other components
of the VLCFA elongation machinery, KAR and TER, which catalyze
the second and forth step, respectively, do use NADPH as a cofac-
tor. Thus, progression of the entire VLCFA elongation cycle seems
to enhance the activity of ELOVL7. Considering that the compo-
nents of the VLCFA elongation machinery are known to constitute
an elongase complex [7,12,13,16,17], we speculate that removal of
the reaction product and transfer to the next subunit is required for
the subsequent round of reactions. For example, the reaction prod-
uct of ELOVL7, 3-ketoacyl-CoA, must be removed by KAR to resume
the next condensation reaction of ELOVL7. Without this removal
step, 3-ketoacyl-CoA may continue to occupy the reaction pocket
of ELOVL7.
Our analysis presented here opens the way to analyzing other
puriﬁed ELOVLs. Determination of the kinetic parameters of all
ELOVLs will be required to evaluate the actual involvement of each
ELOVL in FA elongation reactions. Moreover, the in vitro assay
system described here may be useful in developing drugs forcertain ELOVL-associated disorders, for example by screening for
inhibitors.
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